ANAPC11 and cancer: Given that cancer cells with weak mitotic checkpoints or rapid slippage are often resistant to microtubule‐targeting drugs, strategies that delay mitotic exit may enhance the efficacy of such drugs.[42] In line with this, previous studies have shown that the APC/C inhibitor proTAME sensitizes cancer cells to paclitaxel by inhibiting mitotic exit.[21] Consistently, we found that knockdown of APC2 or APC11, both essential APC/C components, sensitized HeLa cells to paclitaxel (Figure S6d, Supporting Information).